Xcout Intel
Corcept Therapeutics Incorporated competitors & alternatives
The 12 closest competitors and alternatives to Corcept Therapeutics Incorporated among pharmaceuticals companies — ranked by similarity to what Corcept Therapeutics Incorporated actually does, not by market-cap band.
Subscribe to see Corcept Therapeutics Incorporated’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company that develops and markets cortisol modulation therapies to treat serious medical conditions. The company focuses on modulating cortisol activity at the glucocorticoid receptor to create novel treatments across therapeutic areas such as endocrinology, oncology, metabolism, and neurology.
Corcept Therapeutics Incorporated at a glance
Corcept Therapeutics Incorporated is a pharmaceuticals company headquartered in United States. Xcout tracks 18 named people at Corcept Therapeutics Incorporated, including Joseph Belanoff (CHIEF EXECUTIVE OFFICER, PRESIDENT AND DIRECTOR). Xcout recorded 136 job postings from Corcept Therapeutics Incorporated in the last 90 days, naming tools such as Tableau, NetSuite, ADP.
Corcept Therapeutics Incorporated leadership
- Joseph BelanoffCHIEF EXECUTIVE OFFICER, PRESIDENT AND DIRECTOR
- Monica TelladoPRESIDENT, EMERGING MARKETS
- Roberto VieiraPRESIDENT, ONCOLOGY
- Sean MaduckPRESIDENT, ENDOCRINOLOGY
- Atabak MokariCHIEF FINANCIAL OFFICER
- Amy FloodCHIEF HUMAN RESOURCES AND COMMUNICATIONS OFFICER
12 more named people on record for Corcept Therapeutics Incorporated, with roles, board committees and tenure — see the full roster →
Hiring at Corcept Therapeutics Incorporated
Xcout recorded 136 job postings from Corcept Therapeutics Incorporated in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Corcept Therapeutics Incorporated's job postings
The weekly hiring trend, the roles and locations behind it — see Corcept Therapeutics Incorporated's hiring signals →
Top 12 Corcept Therapeutics Incorporated competitors
Ranked by semantic similarity — how close each company is to Corcept Therapeutics Incorporated by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Similar pharmaceuticals company
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Pharmaceuticals, Biotechnology & Life Sciences
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
Pharmaceuticals (Drug Delivery)
Camurus is an international pharmaceutical company that develops and provides innovative, long-acting treatments for patients with severe and chronic conditions. The company focuses on therapeutic areas including the central nervous system, rare diseases, endocrinology, oncology, and supportive care.
Similar pharmaceuticals company
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Similar pharmaceuticals company
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Similar pharmaceuticals company
Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company dedicated to delivering transformational medicines, such as QINLOCK, to patients for the treatment of cancer and rare diseases.
Similar pharmaceuticals company
Cortene Inc. is a biopharmaceutical startup headquartered in Burlingame, California, focused on drug development and unraveling diseases of dysregulation.
Similar pharmaceuticals company
Sparrow Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing targeted cardiometabolic therapeutics. The company aims to address conditions such as diabetes and endocrine diseases with precision therapies.
Similar pharmaceuticals company
Ipsen is a global biopharmaceutical company that researches, develops, and commercializes innovative medicines. It primarily serves patients suffering from conditions in the fields of oncology, rare diseases, and neuroscience.
Similar pharmaceuticals company
Servier is an international pharmaceutical company that researches, develops, and provides medical treatments primarily focused on oncology, cardio-metabolic diseases, and neurology. The company serves patients globally by delivering therapeutic innovations and advancing research in areas such as rare diseases and chronic conditions.
Similar pharmaceuticals company
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Corcept Therapeutics Incorporated and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Corcept Therapeutics Incorporatedand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →